New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies

Eslam B. Elkaeed, Mohammed S. Taghour, Hazem A. Mahdy, Wagdy M. Eldehna, Nehal M. El-Deeb, Ahmed M. Kenawy, Bshra A. Alsfoug, Mohammed A. Dahab, Ahmed M. Metwaly, Ibrahim H. Eissa, Mohamed A. El-Zahabi

Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, 13713, Saudi Arabia; Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt; Department of Pharmaceutical Chemistry, Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt

ABSTRACT

New quinoline and isatin derivatives having the main characteristics of VEGFR-2 inhibitors was synthesised. The antiproliferative effects of these compounds were estimated against A549, Caco-2, HepG2, and MDA-MB-231. Compounds 13 and 14 showed comparable activities with doxorubicin against the Caco-2 cells. These compounds strongly inhibited VEGFR-2 kinase activity. The cytotoxic activities were evaluated against Vero cells. Compound 7 showed the highest value of safety and selectivity. Cell migration assay displayed the ability of compound 7 to prevent healing and migration abilities in the cancer cells. Furthermore, compound 7 induced apoptosis in Caco-2 through the express down-regulation of the apoptotic genes, Bcl2, Bcl-xl, and Survivin, and the upregulation of the TGF gene. Molecular docking against VEGFR-2 emerged the interactions of the synthesised compounds in a similar way to sorafenib. Additionally, seven molecular dynamics simulations studies were applied and confirmed the stability of compound 13 in the active pocket of VEGFR-2 over 100 ns.

1. Introduction

The WHO estimated the number of global deaths because of cancer to be more than ten million humans in 2020. Among them, 935,000 people died because of colon and rectum cancer. Colon cancer was described by the NHS as one of the four most common cancer types. It was estimated that from 2007 to 2016 both incidence and mortality of colorectal cancer increased in countries that have medium and high Human Development Index as well as in the younger people. The global number of new cases diagnosed with colorectal cancer was 1,096,601 in 2018.

Apoptosis originated from a Latin word that means “to fall off” and scientifically can be defined as programmed cell death. In the early stages of growth, apoptosis is the mechanism that the body uses to get rid of unwanted cells such as the soft tissues between the fingers of the growing hand. Apoptosis is the main mechanism utilised by the human body to eliminate damaged cells. Apoptosis plays a crucial role in the process of cancer prevention and treatment. The blockage of apoptosis in a cell resulted in its uncontrolled division and subsequently its development to be malignant. In order to survive and expand, malignant cells utilise various strategies to modulate the apoptotic signals inhibiting apoptosis at both protein and genetic levels.

Vascular Endothelial Growth Factor (VEGF) family exhibited strong antiapoptotic activities in addition to its effect as angiogenesis promoters. VEGF is described as the strongest pro-angiogenic protein. VEGF potentiates the proliferation as well as the tube formation of endothelial cells. Also, VEGF induces endothelial nitric oxide synthase causing vasodilatation. VEGF exhibits its effect via binding with certain receptors on the cell surface. These receptors are the tyrosine kinase receptors including VEGF receptor-1 (VEGFR-1) besides VEGFR-2. The interaction of VEGF to the receptor’s extracellular domain results in the activation of a cascade of downstream enzymes. VEGFR-2 was identified as the major key receptor that mediates the pro-angiogenic activities of VEGF.
be employed in the discovery of active and safe candidates. Computational chemistry has the privilege of limiting time, efforts, and costs in addition to saving animal lives\textsuperscript{15–17}. Various in silico methods were employed successfully in drug design, discovery, DFT, ADMET, and toxicity of new drugs\textsuperscript{18}.

Our teamwork employed the in silico drug design approach to discover various novel VEGFR-2 inhibitors. The designed candidates were synthesised and examined against the VEGFR-2 enzyme. These candidates were belong to various chemical classes such as quinazoline\textsuperscript{19}, quinoxaline-2 (1H)-one\textsuperscript{20}, and thieno[2,3-d]pyrimidine\textsuperscript{21}.

Based on our attempts to develop potent anti-VEGFR-2 inhibitors, two novel sets of quinoline-thiazolidine-2,4-dione and isatin-thiazolidine-2,4-dione hybrids were produced through the modification of some reported inhibitors of VEGFR-2. The targeted candidates were designed to maintain the key pharmacophoric characteristics of inhibitors of VEGFR-2, and they were tested to demonstrate their cytotoxic activities against human malignant cell lines as well as their inhibitory activities against the VEGFR-2 protein.

### 1.1. Rationale

VEGFR-2 inhibitors have four key pharmacophoric features, according to prior publications. (i) A hetero aromatic ring structure capable of engaging Cys917 at the hinge region\textsuperscript{22}. (ii) A spacer moiety capable to be directed in the spacer region of the active site\textsuperscript{23}. (iii) A pharmacophore moiety (e.g. amide or urea) that can bind to Glu883 and Asp1044 at the DFG motif region. (iv) A hydrophobic group resides in the allosteric pocket of the VEGFR-2 binding site\textsuperscript{24}.

Quinoline, isatin, and thiazolidine-2,4-dione are three scaffolds that have great interest in the field of drug synthesis and discovery. These scaffolds were observed in many reported anticancer agents, especially VEGFR-2 inhibitors. Three FDA VEGFR-2 inhibitors (lenvatinib, 2, tivozanib, 3, and lucitanib, 4) comprise the quinoline moiety as a hetero aromatic system. Another FDA VEGFR-2 (sunitinib, 5) comprises the isatin moiety. In addition, sunitinib, 5, comprises the 2,4-dimethyl-1H-pyrrole moiety as a linker (Figure 1).

Utilising ligand-based drug design, especially the molecular hybridisation strategy that entails the connection of two or more groups with significant biological capabilities\textsuperscript{25}, Two series of VEGFR-2 were design new hybrids of quinoline-thiazolidine-2,4-dione (compounds 7, 8, and 9) and isatin-thiazolidine-2,4-dione (compounds 13 and 14). As shown in Figure 2, the heteroaromatic system was designed to be quinoline or isatin moieties. The linker group was the thiazolidine-2,4-dione moiety as a ring equivalent for 2,4-dimethyl-1H-pyrrole of sunitinib with increased the advantage of being a good centre for hydrogen bonding interactions and enhancement of water solubility of the synthesised compounds. The pharmacophore moiety was kept to be an amide group in all the designed compounds. The terminal hydrophobic moiety was kept to be different substituted aromatic structures.

### 2. Results and discussion

#### 2.1. Chemistry

The synthetic pathways adopted to obtain the target compounds are presented in Schemes 1 and 2. Firstly, the synthesis of the key starting compound 2 (2-chloro-6-methoxyquinoline-3-carbaldehyde) (Scheme 1) was achieved through chlorination, formylation, and cyclisation of N-(4-methoxyphenyl)acetamide 1 using DMF/POCl\textsubscript{3} to give 2-chloro-6-methoxyquinoline-3-carbaldehyde 2, according to the reported procedure\textsuperscript{26}. On the other hand, refluxing the thiourea 3 with 2-chloroacetic acid 4 in water contains 4 N HCl afforded thiazolidine-2, 4-dione 5\textsuperscript{27}. The condensation of compound 5 with 2-chloro-6-methoxyquinoline-3-carbaldehyde 2 in glacial acetic acid/sodium acetate mixture in accordance with the Knoevenagel condensation\textsuperscript{28}, furnished the final benzylidine product 6. Treatment of compound 6 with 2-chloroacetamide derivatives in refluxing DMF using anhydrous K\textsubscript{2}CO\textsubscript{3} as base and...
KI as a nucleophilic catalyst to afford the target derivatives 7, 8, and 9.

$^1$H NMR spectra 7, 8, and 9 showed the appearance of aliphatic protons of the methylenes as shielded singlet signals at 4.49–4.55 ppm, and singlet signals around $\delta$ 3.50 ppm of the methoxy group. In addition, the benzylidene methine protons exhibited singlet signals in the range of $\delta$ 7.98–7.99 ppm. This methine was also detected in the $^{13}$C NMR spectra at $\delta$ of 142.0 ppm. Moreover, their $^1$H NMR spectra revealed the presence of two NH protons at $\delta$ ranges of 10.24–10.43 ppm and 12.15–12.16 ppm. In addition, $^{13}$C NMR showed the presence of a methylene carbon in the $\delta$ range of 46.73–56.03 ppm. Two amide carbonyls were displayed in the $^{13}$C NMR spectrum at the $\delta$ range of 166.1–160.5 ppm.

Synthesis of compound 11 (Scheme 2) was achieved via refluxing of thiazolidine-2,4-dione 4 with isatin 10 in glacial acetic acid and anhydrous sodium acetate. Consequent treatment of 11 with alcoholic potassium hydroxide provided the corresponding salt 12. Heating of 12 with 2-chloroacetamide derivatives in dry DMF afforded the target compounds 13 and 14. $^1$H NMR spectra data showed shielded singlet signals of the methylene protons (aliphatic) at the $\delta$ range of 4.55–4.59 ppm. In addition to 2NH protons at the $\delta$ ranges of 10.38–10.49 ppm and 11.31–11.34 ppm.

2.2. Biological evaluation

2.2.1. In-vitro anticancer effects

To assess the antiproliferative effects of the targeted candidates, an MTT assay was performed against four cancer cell lines: lung carcinoma epithelial (A549), colon cancer (Caco-2), hepatocellular cancer (HepG2), and breast cancer (MDA-MB-231). The results were listed in Table 1 as IC$_{50}$ values.

The results revealed that Caco-2 cells are the most sensitive cell line against the targeted candidates. In descending pattern, compounds 14, 13, and 7 are the most active candidates against Caco-2 cells with IC$_{50}$ values of 5.7, 9.3, and 93.5 M, respectively. Interestingly, compounds 13 and 14 showed comparable activity with that of doxorubicin against Caco-2 cells (IC 50 = 8.2 M). Compounds 13 and 14 are 0.88 and 1.44 times as active as doxorubicin. In addition, compound 14 was the most active member against MDA-MB231 cells showing an equal IC$_{50}$ value (9 M) to that of doxorubicin.

From the results of cytotoxicity against the four cell lines, it can be deduced that isatin derivatives (13 and 14) are more cytotoxic than quinoline derivatives (7, 8, and 9) against three cell lines (A549, Caco-2, and MDA-MB-231). Furthermore, by comparing the cytotoxicity of the tested compounds against the Caco-2
cell line, we can reach available structure-activity relationships regarding the hydrophobic tail. It was found that the phenyl ring is more advantageous as a hydrophobic tail than \( p \)-methoxy-phenyl moiety, and the latter is more beneficial for activity than \( o \)-tolyl moiety.

2.2.2. VEGFR-2 inhibition

As the main target in this work is the design and synthesis of promising VEGFR-2 inhibitors, we subjected the synthesised compounds to in vitro VEGFR-2 inhibitory assay to assess the ability of these compounds to obstacle the kinase activity of VEGFR-2. The results were summarised in Table 2 as IC{sub 50} values in a nanomolar unit.

The results revealed that the isatin derivatives (compounds 13 and 14) are the most active members exhibiting strong IC{sub 50} values of 69.11 and 85.89 nM, respectively. Compounds 13 and 14 were 0.78 and 0.70 times as active as sorafenib (IC{sub 50} = 53.65 nM). Additionally, compound 9 showed moderate VEGFR-2 inhibitory activity with an IC{sub 50} value of 98.53 nM (0.54 times of sorafenib). On the other hand, compounds 7 and 8 showed weak activities with IC{sub 50} values of 137.40 and 187.00 nM, respectively.

2.2.3. Cytotoxicity against normal cell lines

The cytotoxic activities of the synthesised against normal cells were evaluated against the Vero cell line utilising an MTT assay. The results were summarised in Table 3.

The results disclosed that the quinoline derivatives (compounds 7, 8, and 9) have very low cytotoxicity against Vero cells with IC{sub 50} values of 440, 150, and 196 \( \mu \)M, respectively. Although the isatin derivatives (compounds 13 and 14) expressed higher cytotoxicity against the normal cells with IC{sub 50} values of 26.5 and 30 \( \mu \)M, respectively, the obtained results were safer than doxorubicin which showed an IC{sub 50} value of 25 \( \mu \)M. These results indicated the higher safety of quinoline derivatives over the isatin.

2.2.4. Selectivity index (SI)

For further evaluation of the toxicity of the synthesised compounds, the selectivity index (SI) of these compounds was calculated. SI is the ratio of the IC{sub 50} value on normal cells to the IC{sub 50} value on cancer cells\(^2\). A compound with SI lower than 1 is considered to be toxic\(^3\).

From the results of SI presented in Table 4, it can be observed that the SI of quinoline derivatives (7 and 9) are higher than 1 in the examined cell lines. Also, compound 8 revealed safe results against HepG2 and MDA-MB231 cell lines. On the other hand, the isatin derivatives showed SI values lower than 1, indicating their lower selectivity against normal cells (Figure 3). Accordingly, compound 7 of the highest selectivity index was selected for further biological analysis.

2.2.5. Wound healing assay (migration assay)

In-vitro scratch assay\(^3\) was performed for compound 7 as it was the safest compound exhibiting the highest selectivity index.
Table 1. *In vitro* anti-proliferative activities.

| Compounds | A549 IC₅₀ (µM) | Caco-2 IC₅₀ (µM) | HepG2 IC₅₀ (µM) | MDA-MB231 IC₅₀ (µM) |
|-----------|----------------|-----------------|-----------------|-------------------|
| 7         | 159 ± 14       | 93.5 ± 0.71     | 150 ± 7.07      | 122.5 ± 7.01      |
| 8         | 196 ± 70       | 189.5 ± 9.11    | 134 ± 1.41      | 130 ± 5.60        |
| 9         | 51 ± 4.20      | 167 ± 4.20      | 145 ± 3.50      | 188 ± 7.01        |
| 13        | 49.5 ± 0.70    | 9.3 ± 0.421     | 149 ± 9.80      | 28 ± 0.50         |
| 14        | 54 ± 1.40      | 5.7 ± 0.07      | 149 ± 7.01      | 9 ± 0.51          |
| Doxorubicin| 7 ± 0.22       | 8.2 ± 0.21      | 2.8 ± 0.07      | 9 ± 0.77          |

*The results were the mean of three replicates.

Table 2. VEGFR-2 inhibitory assay for the targeted candidates and sorafenib.

| Compounds | VEGFR-2 IC₅₀ (nM) |
|-----------|------------------|
| 7         | 137.40           |
| 8         | 187.00           |
| 9         | 98.53            |
| 13        | 68.11            |
| 14        | 85.89            |
| Sorafenib | 53.65            |

*The results were the mean of three replicates.

Table 3. Cytotoxicity of the targeted candidates against the Vero cell line.

| Compounds | Cytotoxicity (IC₅₀ (µM)) |
|-----------|--------------------------|
| 7         | 440 ± 14.10              |
| 8         | 150 ± 14.10              |
| 9         | 196 ± 2.80               |
| 13        | 26.5 ± 1.71              |
| 14        | 30 ± 1.35                |
| Doxorubicin| 25 ± 1.41                |

Table 4. Selectivity index of the synthesised compounds.

| Compounds | A549 Selectivity Index | Caco-2 Selectivity Index | HepG2 Selectivity Index | MDA-MB231 Selectivity Index |
|-----------|------------------------|--------------------------|-------------------------|-----------------------------|
| 7         | 2.77                   | 4.71                     | 2.93                    | 3.59                        |
| 8         | 0.77                   | 0.79                     | 1.12                    | 1.15                        |
| 9         | 3.84                   | 1.17                     | 1.35                    | 1.04                        |
| 13        | 0.54                   | 2.85                     | 0.18                    | 0.95                        |
| 14        | 0.06                   | 0.61                     | 0.02                    | 0.39                        |
| Doxorubicin| 3.57                   | 3.05                     | 8.93                    | 2.78                        |

2.2.7. Cell cycle analysis

Employing the flowcytometry technique, the cell cycle pattern of the untreated Caco-2 cancer cells (Figure 6(A)) was compared with that of the treated cells with compound 7. The cell cycle pattern of Caco-2 cell line after treatment (Figure 6(B)) showed a decrease in the cell population in G₀/G₁ and S phases (46.4 and 13.1%, respectively) compared with the untreated cells (51.7 and 24.7%, respectively) which means the considered compound caused a cellular arrest in sub G₀ (Apoptotic phase).

2.3. In silico (computational) studies

2.3.1. Molecular docking

Molecular docking experiments were applied for the considered compounds to clarify their proposed binding modes against VEGFR-2 (PDB ID: 2OH4) using sorafenib as a reference. Table 5 summarises the calculated binding energies (ΔG) of the tested compounds and sorafenib.

| Compounds | A549 SI Values | CaCo-2 SI Values | HepG2 SI Values | MDA-MB231 SI Values |
|-----------|----------------|-----------------|-----------------|---------------------|
| 7         | 7              | 8               | 9               | 13                  |
| 8         | 8              | 9               | 13              | 14                  |
| 9         | 9              | 13              | 14              | Doxorubicin         |
| 13        | 13             | 14              | Doxorubicin     |                      |
| 14        | 14             | Doxorubicin     |                  |                      |

In this test, Caco-2 cells were allowed to grow then, a wound was formed on the cell layer. Next, the cells were incubated with the sub IC₅₀ dose of compound 7. The results of wound healing were compared to the untreated cell line. Figure 4 illustrates the degree of wound healing caused by compound 7 compared to the control cells.

From Figure 4(A) (the treated cells), it can be noticed that the diameter of the wound is equal to 0.3058 mm. on the other hand, Figure 4(B) (the control cells) showed a diameter of 0.276 mm. The wound was completely closed within 24 h as appeared in Figure 4(C). Such findings indicate the ability of compound 7 to prevent wound healing in the cancer population at a low concentration.

Apoptosis is an important mechanism for fighting the tumour. The apoptosis process comprises many gene families such as p53, caspases, and Bcl-2. The apoptosis mechanism is controlled by the balance between the pro-apoptotic and anti-apoptotic mediators. The Bcl-2 family (Bcl2 and Bcl-xl) is a well-known example of anti-apoptotic mediators. Moreover, Survivin is an example of the overexpressed pro-survival protein in various cancer cells. Furthermore, the transforming growth factor (TGF) is an example of a pro-apoptotic mediator that suppresses and controls proliferation of malignant cells in its early stages.

RT-qPCR technique was applied to assess the expression levels of Bcl2, Bcl-xl, Survivin, and TGF in Caco-2 cells after treatment with compound 7 for 24 h. As shown in Figure 5, compound 7 exhibited an expressive down-regulating potentialities against Bcl2, Bcl-xl, and Survivin genes. On the other hand, such a compound produced an upregulation effect of the TGF gene. Taking these results into consideration, it can be concluded that compound 7 can induce apoptosis in Caco-2.
Compound 7 showed a binding mode like the reference molecule with a docking energy of $-21.94$ kcal/mol. The quinolin-2(1H)-one moiety formed five H.bonds in the hinge region with Leu838, Leu1033, Ala864, and Cys917. The thiazolidine-2,4-dione (linker) moiety formed two H.bonds with Cys1043 and Asp1044. Also, it formed three hydrophobic bonds with Val1914, Phe1045, and Val897. The pharmacophore (amide) moiety occupied the DFG region forming two H.bonds with Glu883 and Asp1044. The terminal phenyl ring occupied the allosteric pocket forming two H.bonds with Leu887 and Val897 (Figure 9).

Compound 8 showed docking energy of $-21.84$ kcal/mol. The quinolin-2(1H)-one moiety formed five H.bonds in the hinge region with Ala864, Leu838, Leu1033, and Val846. The thiazolidine-2,4-dione (linker) moiety formed an extra H.bond with Cys1043 and Asp1044 in addition to three hydrophobic bonds with Val1914, Val914, and Lys866. The pharmacophore (amide) moiety occupied the DFG region forming two H.bonds with Glu883 Asp1044. The terminal phenyl ring occupied the allosteric pocket forming two H.bonds with Leu887 and Val897 (Figure 10).

Compound 9 showed docking energy of $-21.53$ kcal/mol. The quinolin-2(1H)-one moiety formed five H.bonds in the hinge region with Ala864, Leu838, and Leu1033. The thiazolidine-2,4-dione (linker) moiety formed two extra H.bonds with Cys1043 and Asp1044 in addition to three hydrophobic bonds with Val897, Val914, and Phe1045. The pharmacophore (amide) moiety occupied the DFG region forming two H.bonds with Glu883 Asp1044. The terminal phenyl ring occupied the allosteric pocket forming two H.bonds with Leu887 and Val897 (Figure 11).

Figure 4. Effect of compound 7 on wound healing of Caco-2 cells at a concentration of 90 μM. (A) The treated cells with a diameter of 0.3058 mm. (B) the control cells with a diameter of 0.276 mm. (C) The treated cells after 24 h showing complete closure of wound. (D) Diagram of the wound healing test. Determination of apoptotic and anti-apoptotic gene expression.

Figure 5. Relative expression of BCL2, BCLXL, Survivin, and TGF levels in Caco-2 cell line after treatment with 90 μM of compound 7 for 24 h showing an expressive down-regulation potential on the Bcl2, Bcl-xl, and Survivin apoptic genes as well as an upregulation potential on the TGF gene.
Compound 13 showed a good binding mode like that of sorafenib with a docking energy of \(-17.44\) kcal/mol. The indolin-2-one moiety formed eight H.Bs in the hinge region with Cys917, Ala864, Leu838, Leu1033, Phe1045, and Val846. The thiazolidine-2,4-dione (linker) moiety formed one H.B with Lys866, and two hydrophobic bonds with Val914, and Val846. The pharmacophore (amide) moiety occupied the DFG region forming two H.Bs with Glu883 and Phe1044. The terminal phenyl ring occupied the allosteric pocket forming one H.B with Leu887 and one E.B with Asp1044 (Figure 12).

### 2.3.2. In silico ADME analysis

Discovery Studio 4.0 software was used to investigate ADMET parameters of the synthesised compounds utilising sorafenib as a reference. The results were summarised in Table 6. The tested compounds 7, 8, and 9 showed very low BBB penetration levels while compounds 13 and 14 exhibited low BBB penetration power. Hence, these compounds may be devoid of CNS toxicity. The aqueous solubility (A-S) of the tested compounds was predicted to be low while the intestinal absorption (I-A) levels were anticipated to be optimal. All examined compounds were expected to be non-inhibitors for the cytochrome P450 (CYP-2D6). So, the incidence of liver side effects is not expected upon their use. Except for compounds 8 and 14, all the tested members were predicted to bind plasma protein more than 90% (Figure 13).

### 2.3.3. Toxicity studies

Discovery studio software version 4.0 was utilised to compute the predicted toxicity profile of the synthesised candidates as shown in Table 7.
Starting with the Ames prediction model, all candidates were predicted to be non-mutagen. The carcinogenic potency TD50 in mice of the synthesised compounds ranged from 37.833 to 97.051 g/kg, which was safer than sorafenib (17.535 g/kg). The rat maximum tolerated doses (R-MTD) of these candidates were less than that of sorafenib, with the range of 0.018 – 0.048 g/kg. Candidates 13 and 14 showed higher rat oral LD50 values of 1.404 and 1.21 g/kg, respectively than sorafenib (0.890 g/kg) while the other members showed lower oral LD50 values were in the range of 0.509 – 0.838 g/kg. For the rat chronic LOAEL model, except compound 8, the tested compounds showed LOAEL values in the range of 0.005 – 0.040 g/kg. These were safer than sorafenib (0.004 g/kg). All candidates were computed to be non-irritant and mildly irritant against the skin and the eyes, respectively (Table 7).

2.3.4. MD simulation

The Molecular dynamics (MD) simulations experiments are very close to being a routine computational approach in drug discovery. There are two main strengths in the MD studies. Firstly, it can accurately examine both structural and entropic changes in both ligand and target. Secondly, it can track that changes over a definite time and every ultra-short period at an atomic resolution for ligand as well as protein target. Accordingly, MD experiments can accurately estimate the thermodynamics as well as kinetics changes that are associated with ligand-protein binding. These points implemented the MD simulations as a successful tool to examine the structure-function nature of the certain ligand-target complex. It identifies essential areas such as the stability of the certain ligand-target complex, ligand binding energy, and kinetics.

First, the interaction of a compound with a protein’s active site results in structural changes in the protein. Consequently, conformational changes, as well as dynamics of the compound VEGFR-2 complex, were studied as RMSD to understand stability after binding. The results (Figure 14(A)) demonstrated that the
compound 13-VEGFR-2 complex slightly fluctuated to 80 ns and got stabled in the last 20 ns of the MD run. The flexibility of the compound 13-VEGFR-2 complex was examined by RMSF to predict the regions of changes of VEGFR-2 that were affected through the applied MD simulation experiment. Figure 14(B) demonstrates that the binding of compound 13 didn’t make the VEGFR-2 much more flexible. Based on the change in protein volume, $R_g$ identifies the 3D changes of a protein besides its compactness, and the degree of fluctuation during the simulation time. The $R_g$ is inversely proportional to the stability and compactness of the system. The computed $R_g$ values of the compound 13-VEGFR-2 complex in the MD run (Figure 14(C)) remained slightly less than the starting time. Such results indicate the stability and compactness of the compound 13-VEGFR-2 complex. As well as that, SASA calculations were used to determine the compound 13-VEGFR-2 complex’s interaction with the solvents surrounding it. The resulting SASA values reveal how the complex’s conformation changed during the simulation study. Analogously, the SASA values of the compound 13-VEGFR-2 complex were less than the starting period of experiment (Figure 14(D)), indicating that the surface area was reduced and therefore the stability of the compound 13-VEGFR-2 complex was increased. H.Bing is an essential factor capable of stabilising a complex. Therefore, MD simulation experiments were applied to explore the H.Bing through the compound 13-VEGFR-2 complex. Figure 14(E) revealed that compound 13 formed up to two H.Bs with VEGFR-2.

As illustrated in Figure 15, the conformational change analysis of the compound 13-VEGFR-2 complex was performed through the 1(Figure 15(A)), and 100 ns (Figure 15(B)) of the MD production in order to understand the changes caused by binding. The results indicated that minor conformational changes have taken place. Most importantly, compound 13 showed a high degree of binding stability and integrity inside VEGFR-2.

**2.3.5. MM-PBSA study**

Using the MM/PBSA method to calculate the free binding energy from the MD trajectories through the last 20 ns of the MD run applying a 100 ps time interval of, compound 13 demonstrated a very low free binding energy of $-74$ KJ/mol with VEGFR-2.
Interestingly, the binding energy remained stable throughout the entire 20 ns of analysis, showing the accurate binding of the compound 13-VEGFR complex (Figure 16(A)).

Secondly, a total binding free energy analysis of the compound 13-VEGFR-2 complex was performed (Figure 16(B)) to unravel the various components of the obtained binding energy, revealing the particular contributions of amino acids in VEGFR-2 to the binding process. Six residues (VAL-846, ILE-890, VAL-914, LEU-1017, CYS-1043 and PHE-1045) contributed higher binding energy than −4 kJ/mol and are considered key (vital) residues during binding with compound 13.

3. Conclusion

In this work, five new quinoline and isatin derivatives were designed to possess the main features of VEGFR-2. These compounds were synthesised in good yields (74–88%) and confirmed using IR, 1H NMR, and 13C NMR. In vitro anti-proliferative activities were determined against four cancer cell lines (A549, Caco-2, HepG2, and MDA-MB-231). Compounds 13 (IC50 = 9.3 μM) and 14 (IC50 = 5.7 μM) showed comparable activity with doxorubicin (IC50 = 8.2 μM) against Caco-2 cells. Structure-activity relationship revealed that isatin derivatives (13 and 14) are higher cytotoxic agents than quinoline derivatives (7, 8, and 9) against three cell lines (A549, Caco-2, and MDA-MB-231). Furthermore, it was found that the phenyl ring is more advantageous as a hydrophobic tail than p-methoxyphenyl moiety, and the latter is more beneficial for activity than o-tolyl moiety. Compounds 13 and 14 exhibited strong inhibitory effects against VEGFR-2 with IC50 values of 69.11 and 85.89 nM, respectively. The selectivity index test revealed that compound 7 is the safest member. The wound healing assay for compound 7 exhibited the ability of such compound to prevent healing and migration in the cancer population. Compound 7 exhibited a significant down-regulation of Bcl2, Bcl-xl, and Survivin genes, and an upregulation of the TGF gene in Caco-2. The flow-cytometric analysis confirmed the ability of compound 7 to arrest the cellular growth of Caco-2 in sub G0 (apoptotic phase).

Computational studies (docking, ADMET, toxicity, and MD simulations) revealed the good binding mode of the synthesised compounds, an acceptable range of pharmacokinetic properties, and stability in the active site of VEGFR-2 at 100 ns.

4. Experimental

4.1. Chemistry

4.1.1. General

All solvents, reagents, and devices were explained intensely in Supplementary data.

Compounds 2, 5, and 6 were obtained in accordance with the reported protocol41-44. The 1H NMR and 13C NMR analyses were carried out at 400 and 100 MHz, respectively in DMSO-d6 as a solvent. The chemical shifts were presented as ppm. The infra-red analyses were carried out using KBr disc and the results were presented as cm⁻¹. Table 8 showed the colours, yields, and melting points of the target compounds.

4.1.2. Synthesis of compounds 7, 8, and 9

Amixture of compound 6 (0.30 g, 0.001 mol) and anhydrous K2CO3 (0.276 g, 0.002 mol) in DMF (30 ml) was heated in a water bath with the appropriate 2-chloroacetamide derivatives (0.001 mol) for a period of 8 h. Then, the reaction mixture was cooled and poured onto crushed ice. The obtained precipitate was filtered and recrystallized from absolute ethanol to afford compounds 7, 8, and 9, respectively.
4.1.2.1. (Z)-2-[(5-((6-Methoxy-2-oxo-1,2-dihydroquinolin-3-yl)methylene)-2,4-dioxothiazolidin-3-yl)-N-phenylacetamide (7).

IR: 3282, 3141 (NH), 3001 (CH aromatic), 2922 (CH aliphatic), 1737, 1682 (C=O); 1H NMR: 12.16 (s, 1H), 10.43 (s, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.58 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 2.6 Hz, 1H), 7.34 (t, J = 7.8 Hz, 3H), 7.30 (s, 1H), 7.28 (d, J = 2.6 Hz, 1H), 7.10 (t, J = 7.4 Hz, 1H), 4.53 (s, 2H), 3.83 (s, 3H); 13 C NMR: 168.60, 166.16, 164.33, 160.57, 155.08, 142.56, 138.90, 134.39, 129.36, 129.18, 129.08, 127.19, 125.39, 124.17, 123.18, 120.12, 119.64, 117.12, 110.30, 56.03, 31.17; Anal. Calcd. For C21H15N3O4S (405.43).

4.1.2.2. (Z)-2-[(5-((6-Methoxy-2-oxo-1,2-dihydroquinolin-3-yl)methylene)-2,4-dioxothiazolidin-3-yl)-N-(4-methoxyphenyl)acetamide (8).

IR: 3267, 3145 (NH), 3067 (CH aromatic), 2977 (CH aliphatic), 1735, 1681 (C=O); 1H NMR: 12.16 (s, 1H), 10.26 (s, 1H), 8.46 (s, 1H), 8.22 (s, 1H), 7.99 (s, 1H), 7.49 (s, 1H), 7.47 (m, 2H), 7.33 (d, J = 1.8 Hz, 2H), 6.94 (m, 1H), 6.88 (m, 2H), 4.49 (s, 2H), 3.83 (s, 3H), 3.74 (s, 3H); 13 C NMR: 190.37, 161.55, 155.95, 154.99, 142.50, 142.23, 136.50, 134.37, 126.20, 124.16, 121.19, 119.17, 117.28, 114.45, 111.59, 56.04, 55.64, 31.17; Anal. Calcd. For C22H17N3O5S (435.45).

4.1.2.3. (Z)-2-[(5-((6-Methoxy-2-oxo-1,2-dihydroquinolin-3-yl)methylene)-2,4-dioxothiazolidin-3-yl)-N-(o-tolyl)acetamide (9).

IR: 3254, 3224 (NH), 3091 (CH aromatic), 2907 (CH aliphatic), 1722, 1668 (C=O); 1H NMR: 12.15 (s, 1H, NH), 10.24 (s, 1H, NH), 8.43 (s, 1H, H-4, quinolinone), 7.98 (s, 1H, C=CH), 7.45 (m, 1H, 1H, H-8, quinolinone), 7.38 – 7.25 (m, 3H, Ar-H), 7.18 – 7.10 (m, 3H, Ar-H), 6.95 (m, 1H), 4.55 (s, 2H, CH2), 3.35 (s, 3H, OCH3), 2.23 (s, 3H, CH3); 13 C NMR: 171.60, 164.59, 163.70, 161.55, 142.24, 137.75, 136.59, 134.39, 131.73, 131.02 (2), 129.43 (2), 129.31 (2), 126.98 (2), 124.16, 117.28, 111.59, 56.04, 46.73, 17.74; Anal. Calcd. For C22H17N3O4S (419.46).

4.1.3. Synthesis of compounds 13 and 14
A mixture of 12 (0.28 g, 0.001 mol), the appropriate 2-chloroacetamide derivatives (0.001 mol) namely, 2-chloro-N-phenylacetamide and 2-chloro-N-(4-methoxyphenyl) acetamide and KI (0.067 g) in DMF (50 ml) was heated using a water bath for a period of 8 h. Then, cooled and poured onto crushed ice. The obtained precipitate was filtered and recrystallized from absolute ethanol to afford the corresponding compounds 13 and 14 respectively.
4.1.3.1. 2-[2,4-Dioxo-5-(3-oxoindolin-2-ylidene)thiazolidin-3-yl]-N-phenylacetamide (13).

IR: 3293, 3175 (NH), 3060 (CH aromatic), 2943 (CH aliphatic), 1745, 1693 (C=O); 1H NMR: 11.34 (s, 1H, NH), 10.49 (s, 1H, NH), 8.79 (s, 1H, Ar-H), 7.59 (d, J = 7.20 Hz, 2H, Ar-H), 7.36 (m, 1H, Ar-H), 7.34 (m, 2H, Ar-H), 7.11–7.10 (m, 2H, Ar-H), 6.99 (d, 1H, Ar-H), 4.59 (s, 2H, CH2); 13C NMR: 172.51, 170.24, 168.72, 165.71, 164.24, 144.44, 138.87, 133.56, 129.37(2), 128.43, 128.21, 127.19, 124.22, 122.64, 120.23, 119.68, 111.16, 44.13; Anal. Calcd. For C19H13N3O4S (379.39).

4.1.3.2. 2-(2,4-Dioxo-5-(3-oxoindolin-2-ylidene)thiazolidin-3-yl)-N-(4-methoxyphenyl) acetamide 14.

IR: 3293, 3175 (NH), 3060 (CH aromatic), 2943 (CH aliphatic), 1745, 1693 (C=O); 1H NMR: 11.31 (s, 1H), 10.28 (s, 1H), 8.77 (d, J = 8.0 Hz, 1H), 7.49 (d, J = 8.6 Hz, 2H), 7.46 – 7.35 (m, 1H), 7.08 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 7.9 Hz, 1H), 6.91 (d, J = 8.5 Hz, 2H), 4.54 (s, 2H), 3.73 (s, 3H); 13C NMR: 170.26, 168.70, 165.69, 163.71, 155.99, 144.61, 133.52, 131.96, 129.40, 128.42, 128.16, 122.64, 121.25, 120.22, 114.45, 111.13, 55.63, 44.01.

4.2. Biological testing

4.2.1. In vitro anti-proliferative activity

Anti-proliferative activities were assessed using the MTT assay and were explained intensely in Supplementary data.

4.2.2. In vitro VEGFR-2 kinase assay

Was tested using a VEGFR-2 ELISA kit and was explained intensely in Supplementary data.

4.2.3. Safety assay

The safety profiles were examined on Vero cells (non-cancerous cell line) and was explained intensely in Supplementary data.

4.2.4. Selectivity index (SI)

Was calculated and explained intensely in Supplementary data.
4.2.4.1. **Cell Migration assay.** Was performed as the described protocol\(^5\) and was explained intensely in Supplementary data.

4.2.4.2. **Gene expression pattern.** Bcl2, Bcl-xl, TGF and Survivin genes levels were evaluated as reported\(^5\) and was explained intensely in Supplementary data.

4.3. **In silico studies**

4.3.1. **Docking studies**

Were carried out using MOE software\(^5\) and were explained intensely in Supplementary data.

4.3.2. **ADMET studies**

Were determined using Discovery studio 4.0 as reported method\(^5\) and were explained intensely in Supplementary data.

4.3.3. **Toxicity studies**

Were calculated using Discovery studio 4.0 as described\(^5\) and were explained intensely in Supplementary data.

4.3.4. **Molecular dynamics simulation**

MD studies were performed through CHARMM-GUI interface\(^5\) using CHARMM36 force field\(^5\) and NAMD 2.13 package\(^5\) as explained intensely in Supplementary data.

4.3.5. **MM-PBSA studies**

Was performed using **MM-PBSA** package of GROMACS and was explained intensely in Supplementary data.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).
Funding
This research was funded by Princess Nourah bint Abdulrahman University Researchers Supporting Project number [PNURSP2022R142], Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

ORCID
Hazem A. Mahdy http://orcid.org/0000-0002-6620-241X
Ibrahim H. Eissa http://orcid.org/0000-0002-6955-2263

References
1. WHO Cancer. Key facts. https://www.who.int/news-room/fact-sheets/detail/cancer [last accessed 26 Jan 2022].
2. NHS Cancer. Overview. https://www.nhs.uk/conditions/cancer/ [last accessed 27 Jan 2022].
3. Wong MC, Huang J, Lok V, et al. Differences in incidence and mortality trends of colorectal cancer worldwide based on sex, age, and anatomic location. Clin Gastroenterol Hepatol 2021;19:955–66. e61.
4. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424.
5. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000;407:796–801.
6. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485–95.
7. Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol 2013;23:620–33.
8. Farghaly TA, Al-Hasani WA, Abdulwahab HG. An updated patent review of VEGFR-2 inhibitors (2017-present). Exp Opin Ther Pat 2021;31:989–1007. (just-accepted).
9. Li Y, Zhang F, Nagai N, et al. VEGF-B inhibits apoptosis via VEGFR-1–mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008;118:913–23.
10. Xiao X, Wu J, Zhu X, et al. Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007;121:2095–104.
11. Otrock ZK, Mahfouz RA, Makarem JA, Shamseddine AI. Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis 2007;39:212–20.
12. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.
13. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–80.
14. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF–receptor signal transduction. Trends Biochem Sci 2003;28:488–94.
15. Marrone TJ, Briggs a, James M, McCammon JA. Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol 1997;37:71–90.
16. Li N, Wang Y, Li W, et al. Screening of some sulfonamide and sulfonylurea derivatives as anti-Alzheimer’s agents targeting BACE1 and PPARγ. J Chem 2020;2020:1–19.
17. Abdel-Aziz HA, Eldehna WM, Fares M, et al. Synthesis, biological evaluation and 2D-QSAR study of halophenyl bis-hydrazones as antimicrobial and antitubercular agents. Int J Mol Sci 2015;16:8719–43.
18. Parmar DR, Soni JY, Guduru R, et al. Discovery of new anti-cancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies. Bioorg Chem 2021;115:105206.
19. Eissa IH, Ibrahim MK, Metwally AM, et al. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg Chem. 2021;107:104532.
20. Alanazi MM, Eissa IH, Alsafi NA, et al. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1760–82.
21. El-Metwally SA, Abou-El-Regal MM, Eissa IH, et al. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg Chem 2021;112:104947.
22. Lee K, Jeong K-W, Lee Y, et al. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur J Med Chem 2010;45:5420–7.
23. Machado VA, Peixoto D, Costa R, et al. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-yl)thio] phenyl ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg Med Chem 2015;23:6497–509.
24. Dietrich J, Hulme C, Hurley LH. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec®, Nexavar® and BIBR-796. Bioorg Med Chem 2010;18:5738–48.
25. Viegas-Junior C, Danuello A, da Silva Bolzani V, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2021;112:104947.
26. Meth-Cohn O, Narine B, Tarnowski B. A versatile new synthesis of 2-chloroquinoline-3-carbaldehydes. J Chem Soc Perkin Trans 1 1981;1520–30.
27. Kar K, Krittenka U, Basu P, et al. Design, synthesis and glucose uptake activity of some novel glitazones. Bioorg Chem 2014;56:27–33.
28. Shih M-H, Yeh M-Y. Access to the syntheses of syndonyl-substituted α, β-unsaturated ketones and 1, 3-dihydro-indol-2-ones by modified Knoevenagel reaction. Tetrahedron 2003;59:4103–11.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
30. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271–7.
31. Thabrew M, Hughes RD, Mcfarlane IG. Screening of hepatoprotective plant components using a HepG2 cell cytotoxicity assay. J Pharm Pharmacol 2011;49:1132–5.
32. Pritchett JC, Naesens L, Montoya J. Treating HHV-6 infections: the laboratory efficacy and clinical use of anti-HHV-6 agents. In: Flambard L, Lautenschlager I, Krueger G, Ablashi D, ed. Human herpesviruses HHV-6A, HHV-6B & HHV-7. 3rd ed. Amsterdam, Netherlands: Elsevier; 2014.

33. Peña-Morán OA, Villarreal ML, Álvarez-Berber L, et al. Cytotoxicity, post-treatment recovery, and selectivity analysis of naturally occurring podophyllotoxins from Bursera fagaroides var. fagaroides on breast cancer cell lines. Molecules. 2016;21:1013.

34. Indrayanto G, Putra GS, Suhud F. Excipients, R. Methodology, Validation of in-vitro bioassay methods: application in herbal drug research. Profiles Drug Subst Excip Relat Methodol. 2021;46:273–307.

35. Liang C-C, Park AY, Guan J-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols 2007;2:329–33.

36. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun 2005;333:336–43.

37. Yang J, Song K, Krebs TL, et al. Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression. Oncogene 2018;37:2532–36.

38. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358–62.

39. Ibrahim MK, Eissa IH, Abdallah AE, et al. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of novel quinoxaline derivatives as potential PPARγ agonists. Biorg Med Chem 2017;25:1496–502.

40. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics simulations using the CHARMM36 additive force field. J Chem Theor Comput 2012;8:1900–1907.

41. Jo S, Kim T, Iyer VG, Im W. CHARMM GUI: a web-based graphical user interface for CHARMM. J Comput Chem 2008;29:1859–65.

42. Brooks BR, Brooks CL, III, Mackerell AD, Jr, et al. CHARMM: the biomolecular simulation program. J Comput Chem 2009;30:1545–61.

43. Lee J, Cheng X, Swails JM, et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/ OpenMM simulations using the CHARMM36 additive force field. J Chem Theor Comput 2016;12:405–13.

44. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem 2005;26:1781–802.

45. Koch A, Tamez P, Pezzuto J, Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol 2005;101:95–9.

46. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics simulations using the CHARMM36 additive force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles. J Chem Theor Comput 2012;8:3257–73.